Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketing shift from BioLine’s internal team to Ayrmid’s subsidiary Gamida Cell. Gamida cell is commercializing Omisirge, a cell therapy for treating blood cancers in patients who need a stem cell transplant. … Read more